<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099240</url>
  </required_header>
  <id_info>
    <org_study_id>14.0185</org_study_id>
    <nct_id>NCT02099240</nct_id>
  </id_info>
  <brief_title>Patients Response to Early Switch To Oral:Osteomyelitis Study</brief_title>
  <acronym>PRESTO:Osteo</acronym>
  <official_title>Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Julio Ramirez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the current literature, investigators hypothesize that patients with osteomyelitis
      who are treated with the standard approach of intravenous antibiotics for the full duration
      of therapy will have the same clinical outcomes as patients treated with the experimental
      approach of intravenous antibiotics with early switch to oral antibiotics.

      The primary objective of this study is to compare patients with osteomyelitis treated with
      the standard approach of intravenous antibiotics for the full duration of therapy versus
      patients treated with intravenous antibiotics with an early switch to oral antibiotics in
      relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy.
      Secondary objectives of the study include the evaluation of adverse events related to the use
      of antibiotics as well as the cost of care evaluated from the hospital perspective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1.1. Background Information Osteomyelitis is a common disease associated with significant
      morbidity and high cost (1). The treatment of osteomyelitis can be challenging requiring
      prolonged administration of antibiotics and extensive surgical procedures. Even when the
      infection is treated, the relapse rate is as high as 20% (2). When a bone is infected, the
      local multiplication of bacteria produces a local inflammatory response with presence of
      neutrophils and macrophages with areas of microthrombi and avascular necrosis. If a
      significant area of avascular necrosis develops, a segment of the bone without any blood
      supply can become separated and form a sequestrum. Since infection of sequestrum occurs in
      most patients with osteomyelitis, it is considered that in addition to antibiotic treatment,
      the patient requires surgical intervention for removal of necrotic bone.

      1.2. Scientific Rationale There is agreement regarding the minimal duration of antibiotic
      therapy for patients with osteomyelitis. Since an infected bone may take 3 to 4 weeks to
      re--‐ vascularize, the duration of therapy should be a minimum of 4 to 6 weeks of
      antibiotics. Because different organisms can cause osteomyelitis, the initial antibiotic
      therapy during hospitalization should include broad--‐spectrum antibiotics to cover the most
      likely organisms. As part of the initial management, a bone biopsy is regularly performed to
      identify the particular etiologic agent. Once the organism and its antimicrobial
      susceptibilities are known, the spectrum of antibiotic therapy is narrowed, and the
      antimicrobial therapy continues with an antibiotic that is targeted according to the
      susceptibility of the identified pathogen. Targeted antibiotic therapy in patients with
      osteomyelitis is usually performed after 3 to 5 days of broad spectrum antibiotics, since
      this is the time required by the microbiology department to generate antimicrobial
      susceptibilities after the bone biopsy is performed. In regard to the route of antibiotic
      administration, the standard approach is to use an intravenous antibiotic.

      1.3. Potential Risks A potential risk for the use of an early switch to oral antibiotics in
      patients with osteomyelitis is that the blood level achieved with oral antibiotics may not be
      high enough to attain clinical resolution of the infection.

      1.4. Potential Benefits There are several potential benefits of using oral antibiotics
      instead of intravenous antibiotics. First, avoiding a peripherally inserted central line
      eliminates the risk of line infection and line--‐associated deep vein thrombosis. An early
      switch to oral antibiotics may also facilitate early hospital discharge. A shorter hospital
      stay will decrease the risk of hospital--‐associated complications such as
      hospital--‐acquired infections. Further, the patients' quality of life may be better without
      a central line. Finally, the total cost of therapy will be significantly reduced with oral
      therapy.

      2. Methods 2.1. Trial design &amp; setting This will be a prospective, randomized, unblinded
      clinical trial to define if the clinical outcomes of patients with osteomyelitis treated with
      the experimental approach of intravenous antibiotics with an early switch to oral therapy is
      non--‐inferior to the current standard approach of intravenous antibiotics for the full
      duration of therapy.

      2.8. Sample Size &amp; Statistical Analysis The null hypothesis for this study will be as
      follows: H0: πs --‐ πe ≤ --‐Δ Where πs is the proportion of clinical failures in the
      intravenous therapy only group, πe is the proportion of clinical failures in the intravenous
      therapy plus early switch to oral therapy group, and Δ is the non--‐inferiority margin. The
      alternative hypothesis will be: HA: πs --‐ πe &gt; --‐Δ We expect that there will be a 20%
      clinical failure rate for the primary outcome in both the intravenous antibiotic therapy
      group and the intravenous antibiotic therapy plus early switch to oral antibiotic therapy
      group. The study will be powered at 80% with Δ of 0.1. A total of 396 patients will be needed
      to obtain a 95% confidence interval for the difference in failure rates between the two
      groups that has a lower limit above --‐Δ. If the lower limit of this 95% confidence interval
      for the 10 difference in clinical failure rates between the two arms is above -Δ,
      non--‐inferiority will be met. Considering that approximately 15% of patients will be lost
      during study follow--‐up, a total of 456 patients will be enroll in the trial to obtain the
      396 patients necessary for final analyses.

      3. Data Quality Management Plan 3.1. Overview of the Clinical and Translational Research
      Support Center

      The University of Louisville Clinical and Translational Research Support Center (CTRSC) will
      be responsible for data collection, data quality, and data analysis for this project. The
      CTRSC (http://www.ctrsc.net) is a multi--‐disciplinary team comprised of professionals in
      medicine, public health, statistics, and computer science. The team has considerable
      experience managing and supporting single--‐site and multi--‐center clinical research
      studies. Specifically, members of the CTRSC will be responsible for:

        -  Study design

        -  Development of data collection forms

        -  Development of study manual 11

        -  Development of electronic Internet base data entry system

        -  Providing instruction on use of forms and data entry system

        -  Development of study database

        -  Tracking subject enrollment

        -  Overseeing data transmission

        -  Providing data management

        -  Handling data validation

        -  Protecting confidentiality of data

        -  Performing feasibility evaluation The data quality team leader for this project will be
           Dr. Robert Kelley with assistance from Dr. Timothy Wiemken and Dr. Paula Peyrani.

      The CTRSC has access to the University of Louisville's high--‐performance computing cluster,
      which consists of 312 IBM iDatplex nodes each with two Intel Xeon quad--‐ core processors for
      2496 total cores. The cluster is equipped with a variety of statistical and bioinformatics
      software including SAS, R, Matlab, ClustalW, and Blast, and C, Fortran, Perl, and Python
      libraries. In addition, the CTRSC has several iMac and IBM--‐compatible workstations with
      several data management and analysis packages installed including R, Matlab, SQL Server 2012,
      SAS, SPSS, Eclipse, Visual Studio .NET 2010, MySQL Server 5.1, Tableau 8.0, and REDCap.

      3.2. Purpose of Data Quality Management Plan

      The purpose of this data quality management plan is outline the procedures and processes
      necessary to:

        1. Ensure the data collection and data management for the study are conducted in a manner
           consistent with University of Louisville standards as well as state and federal
           regulations.

        2. Ensure that data collected are accurate and complete when verified against source
           documents.

        3. Provide approaches for early interception and correction of errors in data collection.

        4. Identify areas where specific education and training efforts regarding data collection
           need to be focused.

        5. Outline the tools that will be used to monitor and assess data quality.

        6. Outline the Data Quality Management Team meeting schedule for this project. 3.3. Data
           Capture Primary data collection will be performed by a qualified study coordinator(s)
           who will abstract subject data from the electronic medical record onto a paper case
           report form. Once the paper case report form is complete, the study coordinator or other
           designee will enter the data into a secure, web--‐based clinical data management system.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Failures</measure>
    <time_frame>1 month</time_frame>
    <description>Clinical failure will be defined as clinical or laboratory evidence of infection collected from the patient's medical record documents.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of adverse events related to the use of antibiotics</measure>
    <time_frame>1 month</time_frame>
    <description>Antibiotic--‐related adverse events will be defined according to the Food and Drug Administration adverse events listed in the package insert of the antibiotic prescribed for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of care from the hospital perspective</measure>
    <time_frame>12 months</time_frame>
    <description>Costs will be calculated from the hospital perspective and will include the costs of the antibiotic therapy, home healthcare (nursing--‐ and infusion--‐related), and length of hospital stay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">456</enrollment>
  <condition>Osteomyelitis</condition>
  <arm_group>
    <arm_group_label>Intravenous antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous antibiotics for the full duration of therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous antibiotic therapy plus early switch to oral antibiotic therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral antibiotics</intervention_name>
    <description>intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type</description>
    <arm_group_label>oral antibiotics</arm_group_label>
    <other_name>Amoxicillin</other_name>
    <other_name>Amoxil®</other_name>
    <other_name>Ampicillin</other_name>
    <other_name>Omnipen®</other_name>
    <other_name>Bacampicillin</other_name>
    <other_name>Spectrobid®</other_name>
    <other_name>Carbenicillin Indanyl</other_name>
    <other_name>Pyopen®, Geogen®, Geocillin®</other_name>
    <other_name>Mezlocillin</other_name>
    <other_name>Mezlin®</other_name>
    <other_name>Piperacillin*</other_name>
    <other_name>Pipracil®</other_name>
    <other_name>Ticarcillin</other_name>
    <other_name>Ticar®</other_name>
    <other_name>Amoxicillin-Clavulanic Acid</other_name>
    <other_name>Augmentin®</other_name>
    <other_name>Ampicillin-Sulbactam*</other_name>
    <other_name>Unasyn®</other_name>
    <other_name>Benzylpenicillin</other_name>
    <other_name>Benpen®</other_name>
    <other_name>Cloxacillin</other_name>
    <other_name>Tegopen®, Coxapen®</other_name>
    <other_name>Dicloxacillin</other_name>
    <other_name>Dycill®, Dynapen®, Pathocil®</other_name>
    <other_name>Methicillin</other_name>
    <other_name>Staphcillin®</other_name>
    <other_name>Oxacillin</other_name>
    <other_name>Prostaphilin®, Bactocil®</other_name>
    <other_name>Penicillin G (Benzathine, Potassium, Procaine)</other_name>
    <other_name>Bicillin® C-R/L-A, Pfizerpen®, Wycellin®</other_name>
    <other_name>Penicillin V</other_name>
    <other_name>Pen-Veek®, Beepen-VK®</other_name>
    <other_name>Piperacillin+Tazobactam*</other_name>
    <other_name>Zozyn®</other_name>
    <other_name>Ticarcillin+Clavulanic Acid</other_name>
    <other_name>Timentin®</other_name>
    <other_name>Nafcillin</other_name>
    <other_name>Unipen®, Nafcil®</other_name>
    <other_name>Cefaclor</other_name>
    <other_name>Ceclor®, Ceclor CD®</other_name>
    <other_name>Cefamandol</other_name>
    <other_name>Mandol®</other_name>
    <other_name>Cefonicid</other_name>
    <other_name>Monocid®</other_name>
    <other_name>Cefotetan</other_name>
    <other_name>Cefotan®</other_name>
    <other_name>Cefoxitin</other_name>
    <other_name>Mefoxin®</other_name>
    <other_name>Cefprozil</other_name>
    <other_name>Cefzil®</other_name>
    <other_name>Ceftmetazole</other_name>
    <other_name>Zefazone®</other_name>
    <other_name>Cefuroxime</other_name>
    <other_name>Kefurox®, Zinacef®</other_name>
    <other_name>Cefuroxime axetil</other_name>
    <other_name>Ceftin®</other_name>
    <other_name>Loracarbef</other_name>
    <other_name>Lorabid®Cefdinir</other_name>
    <other_name>Omnicef®</other_name>
    <other_name>Ceftibuten</other_name>
    <other_name>Cedax®</other_name>
    <other_name>Cefoperazone</other_name>
    <other_name>Cefobid®</other_name>
    <other_name>Cefixime*</other_name>
    <other_name>Suprax®</other_name>
    <other_name>Cefotaxime*</other_name>
    <other_name>Claforan®</other_name>
    <other_name>Cefpodoxime proxetil</other_name>
    <other_name>Vantin®</other_name>
    <other_name>Ceftazidime*</other_name>
    <other_name>Ceptaz®, Fortaz®, Tanicef®</other_name>
    <other_name>Ceftizoxime*</other_name>
    <other_name>Cefizox®</other_name>
    <other_name>Ceftriaxone*</other_name>
    <other_name>Rocephin®</other_name>
    <other_name>Cefepime</other_name>
    <other_name>Maxipime®</other_name>
    <other_name>Azithromycin*</other_name>
    <other_name>Zithromax®</other_name>
    <other_name>Clarithromycin*</other_name>
    <other_name>Biaxin®</other_name>
    <other_name>Clindamycin</other_name>
    <other_name>Cleocin®</other_name>
    <other_name>Dirithromycin</other_name>
    <other_name>Dynabac®</other_name>
    <other_name>Erythromycin</other_name>
    <other_name>E-mycin®, Ery-tab®, Benzamycin®</other_name>
    <other_name>Lincomycin</other_name>
    <other_name>Lincocin®</other_name>
    <other_name>T roleandomycin</other_name>
    <other_name>T ao®</other_name>
    <other_name>Cinoxacin</other_name>
    <other_name>Cinoxacin®</other_name>
    <other_name>Ciprofloxacin*</other_name>
    <other_name>Cipro®</other_name>
    <other_name>Enoxacin</other_name>
    <other_name>Penetrex®</other_name>
    <other_name>Gatifloxacin</other_name>
    <other_name>T equin®</other_name>
    <other_name>Grepafloxacin</other_name>
    <other_name>Levofloxacin</other_name>
    <other_name>Levaquin®, Quixin®</other_name>
    <other_name>Lomefloxacin</other_name>
    <other_name>Maxaquin®</other_name>
    <other_name>Moxifloxacin</other_name>
    <other_name>A velox®</other_name>
    <other_name>Nalidixic acid</other_name>
    <other_name>NegGam®</other_name>
    <other_name>Norfloxacin*</other_name>
    <other_name>Noroxin®</other_name>
    <other_name>Ofloxacin</other_name>
    <other_name>Floxin®</other_name>
    <other_name>Sparfloxacin</other_name>
    <other_name>Zagam®</other_name>
    <other_name>T rovafloxacin</other_name>
    <other_name>T rovan®</other_name>
    <other_name>Imipenem-Cilastatin*</other_name>
    <other_name>Primaxin®</other_name>
    <other_name>Meropenem</other_name>
    <other_name>Merrem®</other_name>
    <other_name>Aztreonam*</other_name>
    <other_name>Azactam®</other_name>
    <other_name>Amikacin*</other_name>
    <other_name>Amikin®</other_name>
    <other_name>Gentamicin</other_name>
    <other_name>Garamycin®</other_name>
    <other_name>Kanamycin</other_name>
    <other_name>Kantrex®</other_name>
    <other_name>Neomycin</other_name>
    <other_name>Mycifradin®, Neo-Fradin®</other_name>
    <other_name>Netilmicin</other_name>
    <other_name>Netromycin®</other_name>
    <other_name>Streptomycin</other_name>
    <other_name>Streptomycin®</other_name>
    <other_name>T obramycin*</other_name>
    <other_name>Tobrex®, Nebcin®</other_name>
    <other_name>Paromomycin</other_name>
    <other_name>Humatin®</other_name>
    <other_name>T eicoplanin</other_name>
    <other_name>T argocid®</other_name>
    <other_name>Vancomycin*</other_name>
    <other_name>Vancocyn®, Lyphocin®</other_name>
    <other_name>Demeclocycline</other_name>
    <other_name>Declomycin®</other_name>
    <other_name>Doxycycline</other_name>
    <other_name>Doxy®, Vibra®, Vibramycin®</other_name>
    <other_name>Methacycline</other_name>
    <other_name>Rondomycin®</other_name>
    <other_name>Minocycline</other_name>
    <other_name>Minocin®</other_name>
    <other_name>Oxytetracycline</other_name>
    <other_name>Terramycin®</other_name>
    <other_name>T etracycline</other_name>
    <other_name>Sumycin®</other_name>
    <other_name>Chlortetracycline</other_name>
    <other_name>Mafenide</other_name>
    <other_name>Sulfamylon®</other_name>
    <other_name>Silver Sulfadiazine</other_name>
    <other_name>SSD®, Silvadene®</other_name>
    <other_name>Sulfacetamide</other_name>
    <other_name>Sultrim®</other_name>
    <other_name>Sulfadiazine</other_name>
    <other_name>Sulfamethoxazole</other_name>
    <other_name>Gantanol®</other_name>
    <other_name>Sulfasalazine</other_name>
    <other_name>Sulfasalazine®,Azulfidine®</other_name>
    <other_name>Sulfisoxazole</other_name>
    <other_name>T rimethoprim-Sulfamethoxazole</other_name>
    <other_name>Bactrim®, Septra®, Cofatrim®, Primsol®</other_name>
    <other_name>Sulfamethizole</other_name>
    <other_name>Thiosulfil Forte®</other_name>
    <other_name>Rifabutin</other_name>
    <other_name>Mycobutin®</other_name>
    <other_name>Rifampin</other_name>
    <other_name>Rifadin®</other_name>
    <other_name>Rifapentine</other_name>
    <other_name>Priftin®</other_name>
    <other_name>Linezolid*</other_name>
    <other_name>Zyvox®</other_name>
    <other_name>Quinopristin+Dalfopristin*</other_name>
    <other_name>Synercid®</other_name>
    <other_name>Bacitracin</other_name>
    <other_name>Baci-IM</other_name>
    <other_name>Chloramphenicol*</other_name>
    <other_name>Chloromycetin®</other_name>
    <other_name>Colistemetate</other_name>
    <other_name>Coly-Mycin® M &amp; S</other_name>
    <other_name>Fosfomycin</other_name>
    <other_name>Monurol®</other_name>
    <other_name>Isoniazid</other_name>
    <other_name>Rifamate®</other_name>
    <other_name>Methenamine</other_name>
    <other_name>Hiprex®, Mandelamine®</other_name>
    <other_name>Metronidazol</other_name>
    <other_name>Flagyl®</other_name>
    <other_name>Mupirocin</other_name>
    <other_name>Bactroban®</other_name>
    <other_name>Nitrofurantoin</other_name>
    <other_name>Macrobid®, Macrodantin®, Furantoin®</other_name>
    <other_name>Nitrofurazone</other_name>
    <other_name>Furacin®</other_name>
    <other_name>Novobiocin</other_name>
    <other_name>Albamycin®</other_name>
    <other_name>Polymyxin B</other_name>
    <other_name>Aerospin®</other_name>
    <other_name>Spectinomycin</other_name>
    <other_name>T robicin®</other_name>
    <other_name>T rimethoprim</other_name>
    <other_name>Proloprim®, Trimpex®</other_name>
    <other_name>Colistin</other_name>
    <other_name>Cycloserine</other_name>
    <other_name>Capreomycin</other_name>
    <other_name>Ethionamide</other_name>
    <other_name>Pyrazinamide</other_name>
    <other_name>Para-aminosalicyclic acid</other_name>
    <other_name>Erythromycin ethylsuccinate + sulfisoxazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intravenous antibiotics</intervention_name>
    <description>intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type</description>
    <arm_group_label>Intravenous antibiotics</arm_group_label>
    <other_name>Amoxicillin</other_name>
    <other_name>Amoxil®</other_name>
    <other_name>Ampicillin</other_name>
    <other_name>Omnipen®</other_name>
    <other_name>Bacampicillin</other_name>
    <other_name>Spectrobid®</other_name>
    <other_name>Carbenicillin Indanyl</other_name>
    <other_name>Pyopen®, Geogen®, Geocillin®</other_name>
    <other_name>Mezlocillin</other_name>
    <other_name>Mezlin®</other_name>
    <other_name>Piperacillin*</other_name>
    <other_name>Pipracil®</other_name>
    <other_name>Ticarcillin</other_name>
    <other_name>Ticar®</other_name>
    <other_name>Amoxicillin-Clavulanic Acid</other_name>
    <other_name>Augmentin®</other_name>
    <other_name>Ampicillin-Sulbactam*</other_name>
    <other_name>Unasyn®</other_name>
    <other_name>Benzylpenicillin</other_name>
    <other_name>Benpen®</other_name>
    <other_name>Cloxacillin</other_name>
    <other_name>Tegopen®, Coxapen®</other_name>
    <other_name>Dicloxacillin</other_name>
    <other_name>Dycill®, Dynapen®, Pathocil®</other_name>
    <other_name>Methicillin</other_name>
    <other_name>Staphcillin®</other_name>
    <other_name>Oxacillin</other_name>
    <other_name>Prostaphilin®, Bactocil®</other_name>
    <other_name>Penicillin G (Benzathine, Potassium, Procaine)</other_name>
    <other_name>Bicillin® C-R/L-A, Pfizerpen®, Wycellin®</other_name>
    <other_name>Penicillin V</other_name>
    <other_name>Pen-Veek®, Beepen-VK®</other_name>
    <other_name>Piperacillin+Tazobactam*</other_name>
    <other_name>Zozyn®</other_name>
    <other_name>Ticarcillin+Clavulanic Acid</other_name>
    <other_name>Timentin®</other_name>
    <other_name>Nafcillin</other_name>
    <other_name>Unipen®, Nafcil®</other_name>
    <other_name>Cefaclor</other_name>
    <other_name>Ceclor®, Ceclor CD®</other_name>
    <other_name>Cefamandol</other_name>
    <other_name>Mandol®</other_name>
    <other_name>Cefonicid</other_name>
    <other_name>Monocid®</other_name>
    <other_name>Cefotetan</other_name>
    <other_name>Cefotan®</other_name>
    <other_name>Cefoxitin</other_name>
    <other_name>Mefoxin®</other_name>
    <other_name>Cefprozil</other_name>
    <other_name>Cefzil®</other_name>
    <other_name>Ceftmetazole</other_name>
    <other_name>Zefazone®</other_name>
    <other_name>Cefuroxime</other_name>
    <other_name>Kefurox®, Zinacef®</other_name>
    <other_name>Cefuroxime axetil</other_name>
    <other_name>Ceftin®</other_name>
    <other_name>Loracarbef</other_name>
    <other_name>Lorabid®Cefdinir</other_name>
    <other_name>Omnicef®</other_name>
    <other_name>Ceftibuten</other_name>
    <other_name>Cedax®</other_name>
    <other_name>Cefoperazone</other_name>
    <other_name>Cefobid®</other_name>
    <other_name>Cefixime*</other_name>
    <other_name>Suprax®</other_name>
    <other_name>Cefotaxime*</other_name>
    <other_name>Claforan®</other_name>
    <other_name>Cefpodoxime proxetil</other_name>
    <other_name>Vantin®</other_name>
    <other_name>Ceftazidime*</other_name>
    <other_name>Ceptaz®, Fortaz®, Tanicef®</other_name>
    <other_name>Ceftizoxime*</other_name>
    <other_name>Cefizox®</other_name>
    <other_name>Ceftriaxone*</other_name>
    <other_name>Rocephin®</other_name>
    <other_name>Cefepime</other_name>
    <other_name>Maxipime®</other_name>
    <other_name>Azithromycin*</other_name>
    <other_name>Zithromax®</other_name>
    <other_name>Clarithromycin*</other_name>
    <other_name>Biaxin®</other_name>
    <other_name>Clindamycin</other_name>
    <other_name>Cleocin®</other_name>
    <other_name>Dirithromycin</other_name>
    <other_name>Dynabac®</other_name>
    <other_name>Erythromycin</other_name>
    <other_name>E-mycin®, Ery-tab®, Benzamycin®</other_name>
    <other_name>Lincomycin</other_name>
    <other_name>Lincocin®</other_name>
    <other_name>T roleandomycin</other_name>
    <other_name>T ao®</other_name>
    <other_name>Cinoxacin</other_name>
    <other_name>Cinoxacin®</other_name>
    <other_name>Ciprofloxacin*</other_name>
    <other_name>Cipro®</other_name>
    <other_name>Enoxacin</other_name>
    <other_name>Penetrex®</other_name>
    <other_name>Gatifloxacin</other_name>
    <other_name>T equin®</other_name>
    <other_name>Grepafloxacin</other_name>
    <other_name>Levofloxacin</other_name>
    <other_name>Levaquin®, Quixin®</other_name>
    <other_name>Lomefloxacin</other_name>
    <other_name>Maxaquin®</other_name>
    <other_name>Moxifloxacin</other_name>
    <other_name>A velox®</other_name>
    <other_name>Nalidixic acid</other_name>
    <other_name>NegGam®</other_name>
    <other_name>Norfloxacin*</other_name>
    <other_name>Noroxin®</other_name>
    <other_name>Ofloxacin</other_name>
    <other_name>Floxin®</other_name>
    <other_name>Sparfloxacin</other_name>
    <other_name>Zagam®</other_name>
    <other_name>T rovafloxacin</other_name>
    <other_name>T rovan®</other_name>
    <other_name>Imipenem-Cilastatin*</other_name>
    <other_name>Primaxin®</other_name>
    <other_name>Meropenem</other_name>
    <other_name>Merrem®</other_name>
    <other_name>Aztreonam*</other_name>
    <other_name>Azactam®</other_name>
    <other_name>Amikacin*</other_name>
    <other_name>Amikin®</other_name>
    <other_name>Gentamicin</other_name>
    <other_name>Garamycin®</other_name>
    <other_name>Kanamycin</other_name>
    <other_name>Kantrex®</other_name>
    <other_name>Neomycin</other_name>
    <other_name>Mycifradin®, Neo-Fradin®</other_name>
    <other_name>Netilmicin</other_name>
    <other_name>Netromycin®</other_name>
    <other_name>Streptomycin</other_name>
    <other_name>Streptomycin®</other_name>
    <other_name>T obramycin*</other_name>
    <other_name>Tobrex®, Nebcin®</other_name>
    <other_name>Paromomycin</other_name>
    <other_name>Humatin®</other_name>
    <other_name>T eicoplanin</other_name>
    <other_name>T argocid®</other_name>
    <other_name>Vancomycin*</other_name>
    <other_name>Vancocyn®, Lyphocin®</other_name>
    <other_name>Demeclocycline</other_name>
    <other_name>Declomycin®</other_name>
    <other_name>Doxycycline</other_name>
    <other_name>Doxy®, Vibra®, Vibramycin®</other_name>
    <other_name>Methacycline</other_name>
    <other_name>Rondomycin®</other_name>
    <other_name>Minocycline</other_name>
    <other_name>Minocin®</other_name>
    <other_name>Oxytetracycline</other_name>
    <other_name>Terramycin®</other_name>
    <other_name>T etracycline</other_name>
    <other_name>Sumycin®</other_name>
    <other_name>Chlortetracycline</other_name>
    <other_name>Mafenide</other_name>
    <other_name>Sulfamylon®</other_name>
    <other_name>Silver Sulfadiazine</other_name>
    <other_name>SSD®, Silvadene®</other_name>
    <other_name>Sulfacetamide</other_name>
    <other_name>Sultrim®</other_name>
    <other_name>Sulfadiazine</other_name>
    <other_name>Sulfamethoxazole</other_name>
    <other_name>Gantanol®</other_name>
    <other_name>Sulfasalazine</other_name>
    <other_name>Sulfasalazine®,Azulfidine®</other_name>
    <other_name>Sulfisoxazole</other_name>
    <other_name>T rimethoprim-Sulfamethoxazole</other_name>
    <other_name>Bactrim®, Septra®, Cofatrim®, Primsol®</other_name>
    <other_name>Sulfamethizole</other_name>
    <other_name>Thiosulfil Forte®</other_name>
    <other_name>Rifabutin</other_name>
    <other_name>Mycobutin®</other_name>
    <other_name>Rifampin</other_name>
    <other_name>Rifadin®</other_name>
    <other_name>Rifapentine</other_name>
    <other_name>Priftin®</other_name>
    <other_name>Linezolid*</other_name>
    <other_name>Zyvox®</other_name>
    <other_name>Quinopristin+Dalfopristin*</other_name>
    <other_name>Synercid®</other_name>
    <other_name>Bacitracin</other_name>
    <other_name>Baci-IM</other_name>
    <other_name>Chloramphenicol*</other_name>
    <other_name>Chloromycetin®</other_name>
    <other_name>Colistemetate</other_name>
    <other_name>Coly-Mycin® M &amp; S</other_name>
    <other_name>Fosfomycin</other_name>
    <other_name>Monurol®</other_name>
    <other_name>Isoniazid</other_name>
    <other_name>Rifamate®</other_name>
    <other_name>Methenamine</other_name>
    <other_name>Hiprex®, Mandelamine®</other_name>
    <other_name>Metronidazol</other_name>
    <other_name>Flagyl®</other_name>
    <other_name>Mupirocin</other_name>
    <other_name>Bactroban®</other_name>
    <other_name>Nitrofurantoin</other_name>
    <other_name>Macrobid®, Macrodantin®, Furantoin®</other_name>
    <other_name>Nitrofurazone</other_name>
    <other_name>Furacin®</other_name>
    <other_name>Novobiocin</other_name>
    <other_name>Albamycin®</other_name>
    <other_name>Polymyxin B</other_name>
    <other_name>Aerospin®</other_name>
    <other_name>Spectinomycin</other_name>
    <other_name>T robicin®</other_name>
    <other_name>T rimethoprim</other_name>
    <other_name>Proloprim®, Trimpex®</other_name>
    <other_name>Colistin</other_name>
    <other_name>Cycloserine</other_name>
    <other_name>Capreomycin</other_name>
    <other_name>Ethionamide</other_name>
    <other_name>Pyrazinamide</other_name>
    <other_name>Para-aminosalicyclic acid</other_name>
    <other_name>Erythromycin ethylsuccinate + sulfisoxazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Only adult patients will be invited to participate in this trial (age ≥ 18 years). A
             patient will be considered a candidate to participate in this trial if the following
             two inclusion criteria are present:

               1. Isolation of an organism from bone culture that is susceptible to intravenous and
                  oral antibiotics.

               2. Plus at least one of the following:

                    -  Evidence of local inflammatory response, manifested as local pain, edema,
                       erythema, warmth, or drainage.

                    -  Evidence of systemic inflammatory response, manifested as fever, elevated
                       C--‐reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), or
                       white blood cell count.

          -  *Osteomyelitis--‐compatible findings on plain radiograph, computed tomography, bone
             scan, magnetic resonance imaging, or positron emission tomography.

               -  Pathology report indicative of osteomyelitis.

        Exclusion Criteria:

          -  A patient will not be considered as a candidate to participate in this study if the
             study team expects the subject to be non--‐compliant with the study follow--‐up clinic
             visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Seligson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julio Ramirez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio A Ramirez, MD</last_name>
      <phone>502-852-1148</phone>
      <email>jarami01@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>David Seligson, MD</last_name>
      <phone>502-852-0923</phone>
      <email>d0seli01@louisville.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Forest Arnold, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Wiemkwn, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Kelley, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Summersgill, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruth Carrico, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Harting, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paula Peyrani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Seligson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Craig Roberts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julio Ramirez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004 Jul 24-30;364(9431):369-79. Review.</citation>
    <PMID>15276398</PMID>
  </results_reference>
  <results_reference>
    <citation>Haas DW, McAndrew MP. Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment. Am J Med. 1996 Nov;101(5):550-61. Review.</citation>
    <PMID>8948280</PMID>
  </results_reference>
  <results_reference>
    <citation>Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med. 1970 Jan 22;282(4):198-206. Review.</citation>
    <PMID>4902833</PMID>
  </results_reference>
  <results_reference>
    <citation>Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis. 2005 May;9(3):127-38. Review.</citation>
    <PMID>15840453</PMID>
  </results_reference>
  <results_reference>
    <citation>Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004439. doi: 10.1002/14651858.CD004439.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;9:CD004439.</citation>
    <PMID>19588358</PMID>
  </results_reference>
  <results_reference>
    <citation>Peyrani P, Allen M, Seligson D, Roberts C, Chen A, Haque N, Zervos M, Wiemken T, Harting J, Christensen D, Ramirez R. Clinical outcomes of osteomyelitis patients infected with methicillin-resistant Staphylococcus aureus USA-300 strains. Am J Orthop (Belle Mead NJ). 2012 Mar;41(3):117-22.</citation>
    <PMID>22530208</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2014</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Julio Ramirez</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Osteomyelitis</keyword>
  <keyword>IV Antibiotics</keyword>
  <keyword>Oral Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Cycloserine</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Colistin</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Methicillin</mesh_term>
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Mupirocin</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
    <mesh_term>Rifapentine</mesh_term>
    <mesh_term>Aztreonam</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Paromomycin</mesh_term>
    <mesh_term>Fosfomycin</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Sulbactam</mesh_term>
    <mesh_term>Polymyxins</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Gatifloxacin</mesh_term>
    <mesh_term>Neomycin</mesh_term>
    <mesh_term>Bacitracin</mesh_term>
    <mesh_term>Polymyxin B</mesh_term>
    <mesh_term>Cefixime</mesh_term>
    <mesh_term>Cefotaxime</mesh_term>
    <mesh_term>Cefoxitin</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Cloxacillin</mesh_term>
    <mesh_term>Cefprozil</mesh_term>
    <mesh_term>Norfloxacin</mesh_term>
    <mesh_term>Penicillin G</mesh_term>
    <mesh_term>Penicillin G Benzathine</mesh_term>
    <mesh_term>Penicillin G Procaine</mesh_term>
    <mesh_term>Streptomycin</mesh_term>
    <mesh_term>Cefdinir</mesh_term>
    <mesh_term>Oxacillin</mesh_term>
    <mesh_term>Nafcillin</mesh_term>
    <mesh_term>Cefpodoxime</mesh_term>
    <mesh_term>Cefpodoxime proxetil</mesh_term>
    <mesh_term>Kanamycin</mesh_term>
    <mesh_term>Ticarcillin</mesh_term>
    <mesh_term>Demeclocycline</mesh_term>
    <mesh_term>Sultamicillin</mesh_term>
    <mesh_term>Penicillin V</mesh_term>
    <mesh_term>Cefoperazone</mesh_term>
    <mesh_term>Dirithromycin</mesh_term>
    <mesh_term>Capreomycin</mesh_term>
    <mesh_term>Ethionamide</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Chloramphenicol</mesh_term>
    <mesh_term>Chloramphenicol succinate</mesh_term>
    <mesh_term>Dicloxacillin</mesh_term>
    <mesh_term>Ticarcillin-clavulanic acid</mesh_term>
    <mesh_term>Ceftizoxime</mesh_term>
    <mesh_term>Lincomycin</mesh_term>
    <mesh_term>Cefaclor</mesh_term>
    <mesh_term>Cefotetan</mesh_term>
    <mesh_term>Ceftibuten</mesh_term>
    <mesh_term>Netilmicin</mesh_term>
    <mesh_term>Oxytetracycline</mesh_term>
    <mesh_term>Quinupristin-dalfopristin</mesh_term>
    <mesh_term>Lomefloxacin</mesh_term>
    <mesh_term>Nalidixic Acid</mesh_term>
    <mesh_term>Enoxacin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Spectinomycin</mesh_term>
    <mesh_term>Novobiocin</mesh_term>
    <mesh_term>Dalfopristin</mesh_term>
    <mesh_term>Virginiamycin</mesh_term>
    <mesh_term>Chlortetracycline</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Methacycline</mesh_term>
    <mesh_term>Sparfloxacin</mesh_term>
    <mesh_term>Grepafloxacin</mesh_term>
    <mesh_term>Loracarbef</mesh_term>
    <mesh_term>Cefmetazole</mesh_term>
    <mesh_term>Cefonicid</mesh_term>
    <mesh_term>Cefamandole nafate</mesh_term>
    <mesh_term>Cefamandole</mesh_term>
    <mesh_term>Benzathine benzylpenicillin, procaine benzylpenicillin, drug combination</mesh_term>
    <mesh_term>Mezlocillin</mesh_term>
    <mesh_term>Carbenicillin indanyl</mesh_term>
    <mesh_term>Carbenicillin</mesh_term>
    <mesh_term>Bacampicillin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Methenamine hippurate</mesh_term>
    <mesh_term>Sulperazone</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Sulfasalazine</mesh_term>
    <mesh_term>Nitrofurantoin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Sulfadiazine</mesh_term>
    <mesh_term>Silver Sulfadiazine</mesh_term>
    <mesh_term>Methenamine</mesh_term>
    <mesh_term>Mafenide</mesh_term>
    <mesh_term>Sulfacetamide</mesh_term>
    <mesh_term>Sulfisoxazole</mesh_term>
    <mesh_term>Cinoxacin</mesh_term>
    <mesh_term>Nitrofurazone</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethizole</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Procaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

